To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

January 15, 2020___

Today's Rundown

Featured Story

Nektar pulls NDA for pain drug after unanimous AdComm rejection

Nektar Therapeutics has withdrawn the new drug application for its opioid oxycodegol after an advisory committee unanimously recommended against approval. The 27-0 vote against approval followed questioning of Nektar’s decision to run one pivotal trial and the extent to which it assessed the risk of abuse. 

Thank you to Rho for sponsoring this year's JPM 2020 coverage.

Top Stories

Galapagos bags option on 4 more Fibrocor programs

Galapagos has struck another deal to expand its fibrosis pipeline, picking up an option to license four Fibrocor programs. The deal comes one year after Galapagos landed global rights to an early-stage idiopathic pulmonary fibrosis treatment in development at Fibrocor.

JPM: 'An embarrassment of riches'—Lyndra CEO Hurter on the promise of ultralong-acting pills

SAN FRANCISCO—After working on cystic fibrosis medicines during her 15 years at Vertex Pharmaceuticals, Patricia Hurter was ready for retirement. She hoped to line up more flexible work she could do while traveling, but when she met with Lyndra CEO Amy Schulman about a potential board position, Schulman offered Hurter her own job instead.

Emendo raises $61M to build on Takeda-partnered gene editing platform

Emendo Biotherapeutics has raised a $61 million series B to take forward programs based on its gene editing platform. The New York-based biotech has worked to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs. 

JPM Tuesday roundup: Pfizer CEO talks up pipeline, bolt-on deals the name of the game in 2020?

SAN FRANCISCO—The second day of the annual J.P. Morgan Healthcare Conference again saw no major M&A deals but did see some of the bigger pharma companies present and talk a little more about their pipelines and R&D.

JPM: Mayo Clinic, nference launch ambitious data platform initiative

SAN FRANCISCO—Just a week after backing its $60 million series B round, the Mayo Clinic has tapped healthcare data analytics firm nference to build out an artificial intelligence-powered engine that will collate its years of clinical research and pathology work into something more searchable.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career.  Learn more.

Resources

[Whitepaper] Assessing the Financial Impact of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.

[Whitepaper] Simplify 21 CFR Compliance Documentation

A digital transformation is taking place in the life sciences industry, from research laboratories to manufacturing facilities. But there has always been a gap in these technologies. Download the whitepaper to learn how this challenge was addressed.

[Whitepaper] Consent and the GDPR: An Essential Guide

This paper discusses some of the challenges that the GDPR will introduce, with a particular focus on its requirements for obtaining verifiable, unambiguous consent.

[Whitepaper] Solutions Overview: 10 Digital Prescriptions for Life Sciences

Download this paper to learn how you can fully digitize all paper processes. By doing so, you will see shorter cycle times, reduced development costs, and greater customer satisfaction.

[Whitepaper] What to Look for in an Informatics Platform for Large Molecule R&D

As emerging modalities transform the needs of life science R&D, how can biotech and pharma companies use modern software approaches to increase productivity and reach breakthroughs faster?

[Presentation] Flexible Manufacturing Strategies

Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible.

[Executive Summary] Overcoming Manufacturing Challenges for Accelerated Drug Development

Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project.

[Whitepaper] Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D

The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more.

[Whitepaper] Telemedicine: Facilitating Clinical Trial Participation

Download this white paper and read the expert feedback that snapIoT has gathered from industry thought leaders on the evolution, evaluation, and use of telemedicine solutions in clinical trials.

[Whitepaper] Are We Transforming in the Right Way? Why Launches Can’t Be Distracted By Empty Promises.

How are your launch strategies can convert “innovation” into value for patients?

[Whitepaper] Modernizing clinical trials with Amazon Web Services (AWS)

From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks

[Whitepaper] Why Partner with CSP’s to Validate Mission Critical Apps in the Cloud?

Why companies leverage the expertize of industry focused cloud service providers to design and build quality systems and facilitate the FDA Validation of Mission Critical Apps in the Cloud.

[Whitepaper] How to Protect your Supply Chain from Security and Compliance Threats Utilizing On-Dose Authentication Technologies

Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication.

[Whitepaper] The Unexpected Key to Building Value in Drug Discovery and Development

Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor.

[Executive Summary] Clinical Supplies - Made to Order

Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric.

[Whitepaper] Digital Twins: Creating Digital Operations Today to Deliver Business Value Tomorrow

This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future.

[Q&A] Embarking Upon the Commercial Manufacturing Journey for a Biologic

In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey.

Events